Clinical trial NCT05203068: Specificity Trial of the Recombinant Tuberculosis Allergen in BCG Vaccinated Healthy Volunteers
Official title: Evaluation of the Specificity of Intradermal Test With Recombinant Tuberculosis Allergen in BCG Vaccinated Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tuberculosis
Keywords: Tuberculosis
TB diagnosis
Tuberculosis skin test
CFP10
ESAT6
Lead sponsor: National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Sponsor class: OTHER_GOV
First posted: 2022-01-24
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study is to test the recombinant tuberculosis skin test in the previously BCG vaccinated healthy adults with low risk of TB development, to determine the test specificity.

Detailed description: Recombinant tuberculosis allergen (RTA) is a recombinant fusion protein CFP10-ESAT6 produced by the prokaryotic cell line. The test is widely used in Russian Federation and CIS countries for the latent TB diagnosis in adults and children over 8 years old. The current clinical study is a prospective, multicenter, open-label study in the cohort of healthy adults, not classified as at risk of tuberculosis, with no clinical symptoms of the disease, with a negative T-SPOT.TB test results, to evaluate the specificity of the RTA test in 72 hours following administration of the product at a dose of 0.2 μg/0.1 mL.

Eligibility criteria: Inclusion Criteria:

1. Signed informed consent for the participation in the study.
2. Age 18 to 30 years
3. A history of BCG vaccination (confirmed by medical documentation and/or the presence of BCG scar)
4. Healthy individual according to physical examination and medical records at screening.
5. Willingness to cooperate and follow the recommendations of the Investigator in accordance with the Protocol.

Exclusion Criteria:

1. A history of tuberculosis or close contact with a patient with active tuberculosis for 5 years prior to the enrollment in the study.
2. Positive T-SPOT.TB test at the enrollment in the study
3. Treatment with drugs affecting immune system within 3 months prior to the enrollment in the study
4. Vaccination against any infections \<1.5 months prior to the enrollment in the study
5. Vaccination with BCG \<6 months prior to the enrollment in the study.
6. The Mantoux test with 2 TU and/or the test with the recombinant tuberculosis allergen was performed less than 6 months prior to the enrollment in the study.
7. Congenital or acquired immunodeficiency.
8. Active disease of the immune system
9. HIV infection.
10. The current condition of the skin interferes with the conduct and reading of skin tests (trauma, skin diseases).
11. A disease in which blood sampling poses a risk to the volunteer (hemophilia, other bleeding disorders) or obstructed venous access.
12. The volunteer currently participates in another clinical study or has participated in another clinical study within 3 months prior to the enrollment in the study.
13. Previous participation in clinical studies of ESAT-6 and/or CFP-10 antigens.
14. Pregnancy, lactation, pregnancy planning.
15. The reluctance of a female person to use effective barrier (including spermicidal gel), hormonal or intrauterine contraceptives during the study.
16. History of alcohol, drug, benzodiazepine, or other substance abuse within the 12 months prior to the enrollment in the study.
17. Use of alcoholic beverages within 24 hours prior to the visit.
18. A condition or disease that, in the opinion of the Investigator, is inappropriate for participation in the study.

Primary outcomes:
measure: Number of the Volunteers With the True Negative RTA Result
timeFrame: hour 72
Secondary outcomes:
measure: Number of Subjects With Local Adverse Reactions Within 72 Hours Following the Intradermal Test Application
timeFrame: hour 72
measure: Number of Participants With General and Local Adverse Reactions Within 28 Days After Administration of RTA
timeFrame: Day 28
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Study officials:
affiliation: National Medical Research Center of Phthisiopulmonology and Infectious Diseases
name: Aleksey V. Kazakov, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: National Medical Research Center of Phthisiopulmonologyand Infectious Diseases
name: Anastasia G. Samoylova, MD
role: STUDY_CHAIR
affiliation: National Medical Research Center of Phtisiopulmonology and Infectious Diseases
name: Valentina A. Aksyonova, Prof.
role: STUDY_CHAIR
References: